PSORIASIS TREATMENT CENTER BUSINESS PLAN

I. Executive Summary

Company Description

Name: Not provided. The clinic is a specialized medical practice in Dallas, Texas, launching in 2026 that operates in the healthcare sector, focused exclusively on the treatment of psoriasis and psoriatic arthritis. It provides a center of excellence for patients needing advanced biologic therapies and phototherapy, staffed by board-certified dermatologists and specialized clinical staff. One line: a dedicated regional specialty clinic for chronic psoriatic disease.

The clinic follows a fee-for-service model in a state-of-the-art clinical environment and delivers personalized, high-quality care through advanced biologic administration, supervised phototherapy, and specialist-led clinical management. It is positioned to become the leading regional provider for chronic psoriatic disease management, targeting adult patients with moderate-to-severe psoriasis and psoriatic arthritis who require specialty therapies. Short-term goal: open and stabilize operations in 2026; long-term goal: establish regional leadership in chronic psoriatic disease care. One line: high-expertise specialty care for patients needing advanced psoriatic treatments.

Problem

Millions of Americans suffer chronic physical discomfort and emotional distress from psoriasis, yet care is fragmented and inconsistent across general dermatology practices.

Patients face long waits, referrals, and volume-driven visits that skip time-intensive treatments; existing providers often lack specialized focus, dedicated equipment, and integrated psychological support.

There is a critical shortage of facilities that combine advanced biologic therapies, phototherapy, and mental-health services, leaving moderate-to-severe psoriatic disease inadequately managed.

Solution

Millions of Americans live with the physical and emotional burden of psoriasis and psoriatic arthritis, yet most dermatology clinics are generalists, causing long wait times, limited access to the latest biologics, and scarce specialized phototherapy equipment. This gap produces poor adherence and suboptimal outcomes.

Dedicated center of excellence in Dallas, Texas consolidates diagnosis, treatment, and monitoring under one roof with dermatologists, physician assistants, and phototherapy technicians. Core services include supervised biologic therapy, narrow-band UVB phototherapy, customized topical regimens, multidisciplinary coordination, and onsite capacity for complex systemic treatments and diagnostics. One-line: a single-location, disease-focused clinic delivering coordinated, advanced care.

Mission Statement

We provide unparalleled expertise and compassionate, cutting‑edge care for people with psoriasis and psoriatic arthritis through personalized treatment plans, advanced medical technology, and a holistic chronic‑disease approach. We are committed to improving quality of life and achieving the best clinical and emotional outcomes for every patient. We serve as the primary resource for patients and referring physicians and set the standard for specialized dermatological care.

Key Success Factors

Our success rests on clinical focus, referral flow, operational efficiency, payer navigation, and patient experience.

• Clinical focus: exclusive specialty in psoriasis drives deeper expertise and better outcomes.
• Referral network: robust physician referrals supply steady, high-acuity patient volume.
• High utilization: operational efficiency and retention target 85% utilization by 2030.
• Payer management: capacity to handle high-cost biologics and insurance complexities reduces treatment friction.
• Premium experience: specialized staff and advanced facility build loyalty and long-term retention.

Financial Summary

The clinic projects a clear revenue and profitability ramp from 2026 to 2028, reaching breakeven in Feb-27.

Financial requirements: minimum cash reserve $230,000 (required Jan-27); total payback achieved in 38 months; breakeven Feb-27; overall IRR 4.58% and ROE 5.45%.

The projected trajectory shows sustainable growth to $2,795,000 EBITDA by Year 5 with a 19 FTE staff.

Funding Requirements

USD 690,000 required to start the clinic and reach breakeven in 14 months (Feb-27).